The increasing incidence of genetic and rare diseases is a major factor driving revenue growth in the Antisense ...

Biogen has pointed to an early readout from a small phase 1 trial as evidence that its antisense oligonucleotide salanersen could help children with spinal muscular atrophy (SMA) who are still ...

Ultragenyx Pharmaceuticals' GTX-102 earns FDA Breakthrough status after early data shows sustained progress in Angelman syndrome patients.

Panelists discuss how exciting ongoing research efforts are expanding similar gene therapy technologies to other muscular ...

A journey through the FDA’s newly released complete response letters gave glimpses into the journeys to market for Eli ...

Biogen Inc. (NASDAQ:BIIB) is one of the most undervalued US stocks according to analysts. On June 25, Biogen announced ...

Phase 3 Aspire study enrollment on track to complete in 2025 Aurora study to evaluate GTX-102 in other Angelman syndrome genotypes and ages expected to initiate later this year NOVATO, Calif., June 27 ...

Detailed price information for Ionis Pharmaceuticals (IONS-Q) from The Globe and Mail including charting and trades.

Emerging oligonucleotides and gene editing therapies offer greater precision, long-term efficacy, and improved adherence in comparison to traditional statin therapies. This is especially true for ...

A recent study involving researchers from the University of Basel reveals that slowing down the intracellular transport of ...